Connect with us

Business

FDA panel urges rejection of experimental Alzheimer’s drug

Published

on

WASHINGTON (AP) — Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.

The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked. The experts warned of multiple “red flags” with the data, which did not initially show any benefit until another analysis with later results.

Friday’s meeting follows months of skepticism about the drug, developed by Cambridge, Massachusetts-based Biogen Inc. and Japan’s Eisai Co.

“Alzheimer’s treatment is a huge, urgent, unmet need,” said panelist Dr. Joel Perlmutter, of Washington University School of Medicine. “But if we approve something with data that is not strong we have the risk of delaying good, effective treatments.”

He was one of eight panelists who voted against the drug’s evidence; one voted that the drug showed “strong evidence” and two members said they were undecided. The panel also rejected the merits of a second study of the drug.

The FDA is not required to follow the group’s guidance but their negative opinion could weigh heavily on the agency’s decision on whether to greenlight the drug. The FDA is expected to make a decision by March.

The Biogen drug, known as aducanumab, does not cure or reverse Alzheimer’s; the claim is that it modestly slows the rate of decline. Current drugs only temporarily ease symptoms and no new options have emerged since 2003.

Much of panel’s commentary was a rejection of the FDA’s viewpoint. Earlier in the day, the FDA’s chief staff reviewer gave a glowing review of the drug, calling study data submitted by Biogen “exceptionally persuasive,” “strongly positive” and “robust.” But an FDA statistician noted flaws and inconsistencies in the results and potential safety issues.

″“It feels like the audio and video on TV are out of sync,” said panel member Dr. Caleb Alexander of Johns Hopkins University.

The drugmakers halted two studies of their drug last year after disappointing results. But several months later the companies reversed course, announcing that a new analysis showed the drug was effective at a higher dose and that the FDA advised that it might warrant approval.

More than 5 million people in the United States and many more worldwide have Alzheimer’s, the most common form of dementia.

The drug is expected to be very expensive and “could bankrupt our health care system” while giving patients false hope, the consumer group Public Citizen warned in comments ahead of the meeting.

The FDA evaluation focuses on safety and effectiveness. But advocates for approval, including the Alzheimer’s Association, are pushing to make need part of the decision.

ABOUT THE DRUG

Aducanumab (pronounced “add-yoo-CAN-yoo-mab”) aims to help clear harmful clumps of a protein called beta-amyloid from the brain. Other experimental drugs have done that but it made no difference in patients’ ability to think, care for themselves or live independently.

It’s a biotech medicine made from living cells, and such drugs are very expensive. No price estimate has been announced for the drug, which is given through an IV once a month.

If aducanumab is approved, it’s expected to be covered by Medicare, the government plan for seniors. The FDA and Medicare are barred from considering cost when reviewing a new drug or treatment.

Even qualifying for the drug could be expensive. It’s only been tested in people with mild dementia from Alzheimer’s or a less severe condition called mild cognitive impairment. To verify a diagnosis has required brain scans that cost $5,000 or more. Insurers including Medicare don’t cover the scans because their benefits are unclear, but that could change if a scan becomes a gateway to treatment.

THE EVIDENCE

Historically, the FDA often required two studies showing safety and effectiveness, but in recent years has relaxed that standard.

Each of the two aducanumab studies enrolled about 1,650 people and were stopped roughly halfway through when it seemed the drug wasn’t working. Biogen says that later results show one study was positive at the highest dose; the second study was clearly negative. The company says an analysis from both studies on people who got the highest dose for the longest time shows benefit.

But there are many questions about the validity of such analyses. Another complication: the studies were changed after they were underway to let some people get a higher dose. And the placebo group in the positive study worsened more than the one in the negative study did, which could help explain why aducanumab appeared better by comparison in that one.

The FDA review largely dismissed safety concerns, including swelling in the brain that occurred in as many as one-third of patients, often leading to discontinuation of the drug.

The FDA should require a third study to test the drug in ideal conditions and get a clear answer, said the Mayo Clinic’s Dr. David Knopman, in an interview ahead of the meeting. He’s on the FDA advisory panel but didn’t participate in Friday’s meeting because he helped lead one study. He and other doctors published a journal report earlier this week arguing against approval.

WHAT IT WOULD MEAN FOR PATIENTS

Nearly a dozen Alzheimer’s patients, family members and doctors urged approval of the drug during a public comment period of the online meeting, saying the move would provide hope to patients and spur development of additional therapies.

But any benefit from the drug “is relatively small,” said Dr. Eliezer Masliah, neuroscience chief at the U.S. National Institute on Aging, commenting before the meeting.

In the positive study, the drug modestly slowed the rate of mental decline — a difference of only 0.39 on an 18-point score of thinking skills. How much that means in terms of being able to live independently, recognize family members or remember things is unclear.

Drugs that remove amyloid may have to be combined with medicines that do other things in the brain, and used early enough before damage occurs, to do much good, Masliah said.

If the drug is approved, the American Academy of Neurology urged the FDA to not make it a broad authorization, which could expose many patients to a medicine that might harm rather than help, and could “overwhelm the health care system.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

2026 Don Quijote Awards finalists and honorees announced in Orlando

Published

on

The Hispanic Chamber of Metro Orlando and Prospera will announce winners in four categories at the Dec. 12 gala at EPCOT.

ORLANDO, Fla. (FNN) — The Hispanic Chamber of Metro Orlando and Prospera named 12 finalists for the 29th annual Don Quijote Awards and announced two honorees, recognizing Pamela Nabors as the Hispanic Community Champion and Eddie Soler for lifetime achievement.

Organizers announced the finalists and honorees Nov. 12 at the GuideWell Innovation Center in Orlando. Winners in four competitive categories will be announced Saturday, Dec. 12, at the World ShowPlace Pavilion at EPCOT.

The annual awards recognize Hispanic entrepreneurs, business professionals and community leaders whose work has helped strengthen Central Florida’s economy and communities.

“What makes the Don Quijote Awards so meaningful is that they celebrate more than professional achievements. They honor the journeys, perseverance, and determination behind each success,” said Ramiro Vazquez, chair of this year’s awards.


Finalists in four categories

Representatives from Walt Disney World Resort, Duke Energy and Orlando Health announced the finalists and honorees.

Award categoryFinalists
Hispanic Micro-Enterprise of the YearTop Builder Roofing, owned by David Torres
Taskon Corp., owned by Henry Serna
Wizards Soccer Academy, owned by Pedro Alcalá Sandoval
Hispanic Enterprise of the YearDiesel Continental Corp., owned by John Fredy León Perdomo and Alvaro León Mendez
JJ’s Hospitality Group, owned by Julio J. Paredes
Lasio Professional Products, owned by Nadine Ramos
Professional of the YearDr. Luis Alberto Isea Mercado, an internal medicine physician at AdventHealth
Richard Bilbao, editor-in-chief of the Orlando Business Journal
Sheila Godfrey, vice president and store manager at TD Bank
Excellence AwardDr. Adela Casas-Melley, chair of the Department of Surgery at Nemours Children’s Health, Florida
Andrea Guzmán, vice president for access and community engagement at the University of Central Florida
Nancy Alvarez, anchor and reporter at WESH 2 News

“Strong businesses build strong communities,” said Pedro Turusina, president and CEO of the Hispanic Chamber of Metro Orlando.

Pamela Nabors named Hispanic Community Champion

Pamela Nabors, president and CEO of CareerSource Central Florida, received the Hispanic Community Champion Award. The awards selection committee presents the honor to a non-Hispanic individual who has helped advance Central Florida’s Hispanic community. The committee considers community service, leadership and efforts to expand opportunities for Hispanic professionals and executives.

Eddie Soler receives Lifetime Achievement Award

The selection committee honored Eddie Soler for his career in health care finance and his service to Central Florida’s Hispanic community. Soler began working at Florida Hospital as a teenager and went on to serve as senior executive officer and chief financial officer of AdventHealth’s multistate divisions. Organizers also cited his leadership at Prospera and his work supporting entrepreneurs and small businesses.

Gala to mark nearly three decades of awards

This year’s theme, “Reflections,” looks back at the people and businesses that have helped shape Central Florida’s Hispanic community. Katia Medina, regional vice president of Prospera, said the theme also looks ahead to the next generation of entrepreneurs and leaders.

The gala will take place Saturday, Dec. 12, at the World ShowPlace Pavilion at EPCOT. Event information is available at the Don Quijote Awards website.

Follow Florida National News, a media partner of the annual Don Quijote Awards Gala, for the latest updates and coverage of the winners.

Continue Reading

Business

Getty Images files for Chapter 11. What comes next for Florida photographers and videographers?

Published

on

Getty expects licensing and contributor payments to continue as it seeks court approval for a restructuring. The case comes as AI puts pressure on generic stock imagery and verified coverage remains valuable to newsrooms.

Florida National News | Nov. 9, 2026

Getty Images is asking a federal bankruptcy court to approve a restructuring that would cut its debt and take the company private while it continues licensing photographs and video. For Florida photographers and videographers who sell work through Getty, the immediate question is whether royalties and assignment payments keep arriving on schedule. The longer-term question is which images and footage buyers will still pay to license as generative artificial intelligence makes some stock visuals easier to produce.

Getty Images Holdings Inc. and six subsidiaries filed for Chapter 11 protection Oct. 21 in Delaware. The company entered the case with support from major financial stakeholders and says it expects to continue serving customers and paying contributors in the ordinary course. The court is scheduled to hear several initial motions Nov. 17 and consider confirmation of the restructuring plan Dec. 15. Getty Images Chapter 11 filing and financing disclosure · Bankruptcy docket and Nov. 17 hearing notice · BankruptcyData on the Dec. 15 confirmation hearing

What drove Getty into bankruptcy?

The proposed plan includes up to $533 million in equity commitments from Getty family and Koch Equity Development affiliates. That amount includes financing and conversion of some existing debt into equity. The plan would cancel existing shares and put the reorganized company under the ownership of those investors. Getty Images restructuring agreement

Getty reported $2.1 billion in debt at the end of June. Its second-quarter results also showed $110.9 million in payments related to a warrant litigation judgment and interest, as well as higher interest costs tied in part to financing for the proposed Shutterstock acquisition. Getty abandoned that deal in July after Britain’s competition regulator conditioned clearance on the sale of Shutterstock’s editorial business. Getty Images second-quarter results · U.K. Competition and Markets Authority on the abandoned merger

Getty’s results show why the bankruptcy matters differently across the industry. Second-quarter creative revenue fell 2.6% from a year earlier to $127.4 million, while editorial revenue rose 9.2% to $96.5 million. The company did not quantify how much of the creative decline was attributable to AI. Getty Images second-quarter results

What Florida contributors should watch

Getty says it expects to maintain normal operations through the restructuring. For freelancers, the next royalty statement and deposit will give them a more direct view of whether the process is affecting their income. A contributor who licenses archive photos, a freelance crew that invoices for assignments and a production company that supplies footage may each have different payment terms. Getty Images restructuring announcement

Contributors can reconcile deposits against statements and keep copies of agreements, invoices and notices. An overdue balance or a notice naming a specific contract warrants a closer look at the applicable court documents and deadlines. After the case, the terms that could affect earnings include royalty rates, exclusivity, subscription payouts and how a distributor packages photos and video.

A hand holds a smartphone in front of a blue and purple network of glowing image thumbnails

An AI-generated illustration for Florida National News’ coverage of Getty Images’ Chapter 11 restructuring and competition from generative AI.

Which Florida assignments are most exposed to AI?

Generic office scenes, beach-themed backgrounds and short lifestyle clips face more direct competition from generative tools. A buyer who needs a mood or setting can generate several options without scheduling a shoot. A buyer who needs footage of a specific launch from Florida’s Space Coast, storm damage in a particular neighborhood or a decisive play at a Tampa Bay Buccaneers game still needs a verifiable record of that event.

Florida’s news, sports and entertainment calendar gives local crews opportunities to supply that record. A videographer covering a major convention in Orlando might have an interview or clean footage that a national outlet missed. A photographer covering a local election might have the only usable image of a concession speech. For archive sales, accurate dates, locations, names and captions help buyers find the material and establish what it shows. Event credentials, assignment agreements and existing licenses can limit which uses a contributor can offer.

Getty is also selling generative AI tools. The company says its image generator is trained on licensed creative content and proprietary data and that licenses carry indemnification under the applicable agreement. That gives Getty a way to sell generated visuals to commercial buyers while continuing to license photographs and footage of real events. Getty Images generative AI terms and training FAQ

Where AP and Reuters fit

The Associated Press and Reuters overlap most directly with Getty in editorial coverage. Both can serve publishers that want additional sources of news photographs and video. Reuters Connect also offers live video and individual picture licensing. AP says its standards prohibit the use of generative AI to create, alter or enhance news photography. Associated Press AI standards · Reuters Connect licensing

AP and Reuters could gain business if publishers add a second supplier or Getty changes its prices, packages or service. Getty’s plan also leaves open a different outcome. If the company emerges with less debt and can invest more in editorial coverage, the two agencies could face a stronger competitor.

What comes next

The December hearing will determine whether Getty can move forward with the proposed plan, subject to the court’s ruling and remaining conditions. Getty has said it expects to complete the restructuring by year-end. For Florida contributors, the near-term measures are whether payments arrive, assignments continue and licensing terms change. The longer-term test is whether distributors and newsrooms will pay enough for distinctive, verified Florida coverage to sustain the people who produce it. Getty Images restructuring announcement · BankruptcyData on the Dec. 15 confirmation hearing

Continue Reading

Business

New AdventHealth Middleton Clinic Brings Pediatric Specialists, Urogynecology Near The Villages

Published

on

The multispecialty clinic features 24 treatment rooms, pediatric imaging and services designed to bring care closer to Middleton families.

MIDDLETON, Fla. (FNN) — Families in Middleton have a new option for pediatric and women’s specialty care with the opening of the AdventHealth Middleton Multispecialty Clinic, according to an Oct. 29 news release from AdventHealth.

Located at 2274 Alder Ave., the clinic brings together pediatric primary care, pediatric cardiology, pediatric orthopedics and women’s urogynecology services. The facility includes 24 treatment rooms, a pediatric X-ray room and spaces for children’s heart screenings.

Bringing care closer to families

Middleton, a master-planned community along Central Parkway, is home to approximately 1,200 families and households, many with residents who work in and around The Villages, according to the release.

For Jenny Trew, whose family was the first to move to Middleton, the new clinic could mean fewer long trips for routine appointments. She has been driving nearly an hour to Clermont for pediatric care for her 13-year-old twin sons, Jasen and Jackson.

“Going to the pediatrician usually means pulling both boys out of school, taking time away from work and making a day out of something that should be pretty simple,” Trew said in the release.

Having a pediatrician in the neighborhood will make it easier to balance health care appointments with work, school, sports and other activities, she said.

Dr. Vanessa Carroll, chief medical officer of AdventHealth for Children, said proximity matters when families are seeking care for a sick or injured child.

“Parents don’t want to take their child to just any doctor. They want someone they can trust, right around the corner,” Carroll said in the release. “Because when your child is sick or injured, an hour-long drive can feel even farther.”

Expanding women’s specialty services

The clinic also provides urogynecology services, including care for urinary incontinence and pelvic floor conditions.

The location gives women a nearby option for specialized treatment aimed at improving comfort, health and quality of life, according to AdventHealth.

“Women spend so much of their lives caring for others, and it can become very easy to put their own health last,” Kristen Toth, vice president of AdventHealth for Women, said in the release. “We want women to know there is care here for them, too.”

The clinic brings AdventHealth for Children and AdventHealth for Women together at one location to serve families through different stages of life.

Supporting students and schools

Middleton’s early childhood centers, two K-8 schools and high school collectively enroll more than 3,000 students, according to the release.

LeAnne Yerk, principal of The Villages Charter Elementary School, said access to nearby pediatric care supports students’ health and readiness to learn.

“As educators, we see firsthand that a child’s ability to learn, grow and thrive in the classroom is deeply connected to their health and well-being,” Yerk said in the release.

She described the clinic’s proximity to schools as an important resource for students and families, helping connect health care with educational support.

Location and appointments

The AdventHealth Middleton Multispecialty Clinic is located at 2274 Alder Ave., Middleton, Florida.

To schedule an appointment, call:

  • Pediatric primary care: 352-467-7862
  • Pediatric cardiology: 352-353-2788
  • Pediatric orthopedics: 407-303-5687
  • Women’s urogynecology: 407-303-1380

For online appointment information, visit MyMiddletonPediatrics.com for children’s services or MiddletonUrogyn.com for women’s services.

Continue Reading
Advertisement
Advertisement Ticket Time Machine ad
Advertisement Orlando Regional REALTOR Association logo
Advertisement Parts Pass App
Advertisement Hispanic Chamber of Commerce of Metro Orlando
Advertisement
Advertisement African American Chamber of Commerce of Central Florida
Advertisement FNN News en Español
Advertisement Indian American Chamber of Commerce logo
Advertisement Florida Sports Channel

FNN Newsletter

Trending